These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19694823)

  • 21. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Emerging Molecular Landscape of Urothelial Carcinoma.
    Solomon JP; Hansel DE
    Surg Pathol Clin; 2016 Sep; 9(3):391-404. PubMed ID: 27523968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer.
    Kipp BR; Tyner HL; Campion MB; Voss JS; Karnes RJ; Sebo TJ; Halling KC; Zhang J
    Am J Clin Pathol; 2008 Oct; 130(4):552-9. PubMed ID: 18794047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
    Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
    Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
    Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
    Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive micropapillary urothelial carcinoma of the bladder.
    Lopez-Beltran A; Montironi R; Blanca A; Cheng L
    Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
    Wild PJ; Fuchs T; Stoehr R; Zimmermann D; Frigerio S; Padberg B; Steiner I; Zwarthoff EC; Burger M; Denzinger S; Hofstaedter F; Kristiansen G; Hermanns T; Seifert HH; Provenzano M; Sulser T; Roth V; Buhmann JM; Moch H; Hartmann A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1798-806. PubMed ID: 19454613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
    Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
    Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients.
    Perrino CM; Eble J; Kao CS; Whaley RD; Cheng L; Idrees M; Hashemi-Sadraei N; Monn MF; Kaimakliotis HZ; Bandali E; Grignon D
    Hum Pathol; 2019 Aug; 90():27-36. PubMed ID: 31054897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas.
    Goto K; Konomoto T; Hayashi K; Kinukawa N; Naito S; Kumazawa J; Tsuneyoshi M
    Mod Pathol; 1997 May; 10(5):428-37. PubMed ID: 9160306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
    Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
    Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
    van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
    J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
    Osunkoya AO; Epstein JI
    Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.